HUBERMAN: As a consequence, people have developed peptide therapeutics that stimulate the release of growth hormone and thereby the release of IGF-1, but not by directly stimulating the growth hormone pathway
For example, individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2) should not take GLP-1 medications due to an increased risk of thyroid tumors
Conclusion BPC-157 represents one of the most promising developments in regenerative medicine, offering a potential solution for those struggling with injuries, digestive issues, and chronic pain
In research it is used in models of obesity and metabolic syndrome
13 C NMR (100 MHz, DMSO-d 6 ) = 163.5, 162.4, 149.6, 149.6, 145.7, 139.3, 139.2, 126.0, 125.4, 116.6, 113.4